Engineering approaches for RNA-based and cell-based osteoarthritis therapies

DeJulius, Carlisle R.; Walton, Bonnie L.; Colazo, Juan M.; d’Arcy, Richard; Francini, Nora; Brunger, Jonathan M.; Duvall, Craig L.

doi:10.1038/s41584-023-01067-4

Cited by 12 publications

(2 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a standardized protocol for the preparation and application of PRP must be established [18]. These observations also align with studies investigating PRP in orthopedic applications, where it has shown promise in promoting tissue regeneration and reducing functional limitations [19,20].…”

Section: Discussionmentioning

confidence: 68%

Platelet-Rich Plasma in the Management of Temporomandibular Joint Pain in Young Adults With Temporomandibular Disorder

Mathpati,

Jain,

Mishra

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Temporomandibular disorder (TMD) encompasses a range of conditions affecting the temporomandibular joint (TMJ) and associated structures, with TMJ pain being a prevalent symptom. Conventional management strategies have limitations, which require the exploration of innovative interventions. Platelet-rich plasma (PRP), known for its regenerative properties, presents a potential therapeutic avenue. This study aims to investigate the effectiveness of PRP in reducing the pain associated with mild TMJ in young adults.Methodology: Participants (n = 128) aged 18 to 35 years with mild TMD were evenly randomized into PRP treatment and placebo control groups. PRP was prepared using a standardized protocol, and intra-articular injections were administered. Placebo injections mimic PRP. Follow-up evaluations were carried out at four and eight weeks after the intervention.Results: The study successfully randomized comparable groups, and the PRP treatment group experienced a significant reduction in TMJ pain (visual analog scale [VAS] score: 6.8 ± 1.2 to 2.1 ± 1.0 at eight weeks, P < 0.001). The PRP treatment also increased the largest opening of the mouth (from 38.2 ± 2.5 to 43.5 ± 3.1, P < 0.001) and the number of lateral movements (12.3 ± 1.5 to 14.9 ± 2.0, P < 0.001), while the placebo group had very few changes. Positive patient-reported outcomes on daily activities were observed, with no serious complications reported in either group.Conclusions: This study provides evidence supporting the efficacy of PRP in reducing TMJ pain, improving jaw function, and improving quality of life in young adults with mild TMD. The results underscore the potential of PRP as a minimally invasive intervention for TMJ disorders.

show abstract

Section: Discussionmentioning

confidence: 68%

Platelet-Rich Plasma in the Management of Temporomandibular Joint Pain in Young Adults With Temporomandibular Disorder

Mathpati,

Jain,

Mishra

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…This property renders miRNAs highly interesting therapeutic targets for restoring NPC functions and reversing IDD phenotypes. Recently, miRNA-based therapeutics have gradually translated from basic research to clinical application in the field of degenerative musculoskeletal diseases [ 10 – 15 ], which offers novel insights into precise miRNA-targeted treatments for IDD. However, the lack of an efficient NPC-specific delivery system hinders the application of miRNA-based therapeutics in vivo [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Effective delivery of miR-150-5p with nucleus pulposus cell-specific nanoparticles attenuates intervertebral disc degeneration

Jiang,

Qin,

Yang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Background The use of gene therapy to deliver microRNAs (miRNAs) has gradually translated to preclinical application for the treatment of intervertebral disc degeneration (IDD). However, the effects of miRNAs are hindered by the short half-life time and the poor cellular uptake, owing to the lack of efficient delivery systems. Here, we investigated nucleus pulposus cell (NPC) specific aptamer-decorated polymeric nanoparticles that can load miR-150-5p for IDD treatment. Methods The role of miR-150-5p during disc development and degeneration was examined by miR-150-5p knockout (KO) mice. Histological analysis was undertaken in disc specimens. The functional mechanism of miR-150-5p in IDD development was investigated by qRT-PCR assay, Western blot, coimmunoprecipitation and immunofluorescence. NPC specific aptamer-decorated nanoparticles was designed, and its penetration, stability and safety were evaluated. IDD progression was assessed by radiological analysis including X-ray and MRI, after the annulus fibrosus needle puncture surgery with miR-150-5p manipulation by intradiscal injection of nanoparticles. The investigations into the interaction between aptamer and receptor were conducted using mass spectrometry, molecular docking and molecular dynamics simulations. Results We investigated NPC-specific aptamer-decorated polymeric nanoparticles that can bind to miR-150-5p for IDD treatment. Furthermore, we detected that nanoparticle-loaded miR-150-5p inhibitors alleviated NPC senescence in vitro, and the effects of the nanoparticles were sustained for more than 3 months in vivo. The microenvironment of NPCs improves the endo/lysosomal escape of miRNAs, greatly inhibiting the secretion of senescence-associated factors and the subsequent degeneration of NPCs. Importantly, nanoparticles delivering miR-150-5p inhibitors attenuated needle puncture-induced IDD in mouse models by targeting FBXW11 and inhibiting TAK1 ubiquitination, resulting in the downregulation of NF-kB signaling pathway activity. Conclusions NPC-targeting nanoparticles delivering miR-150-5p show favorable therapeutic efficacy and safety and may constitute a promising treatment for IDD. Graphical Abstract

show abstract

Mesenchymal stem cells for osteoarthritis: Recent advances in related cell therapy

Lin,

Huang,

Jiao

et al. 2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative joint disease that affects the entire joint and has been a huge burden on the health care system worldwide. Although traditional therapy and targeted cartilage cell therapy have made significant progress in the treatment of OA and cartilage regeneration, there are still many problems. Mesenchymal stem cells from various tissues are the most studied cell type and have been used in preclinical and clinical studies of OA, because they are more widely available, have a greater capacity for in vitro expansion, and have anti‐inflammatory and immunomodulatory properties compared to autologous chondrocytes. This article will systematically review the latest developments in these areas. It may provide new insights for improving OA and cartilage regeneration.

show abstract

Engineering approaches for RNA-based and cell-based osteoarthritis therapies

Cited by 12 publications

References 221 publications

Platelet-Rich Plasma in the Management of Temporomandibular Joint Pain in Young Adults With Temporomandibular Disorder

Platelet-Rich Plasma in the Management of Temporomandibular Joint Pain in Young Adults With Temporomandibular Disorder

Effective delivery of miR-150-5p with nucleus pulposus cell-specific nanoparticles attenuates intervertebral disc degeneration

Mesenchymal stem cells for osteoarthritis: Recent advances in related cell therapy

Contact Info

Product

Resources

About